Gilead Sciences, Inc. vs Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 — how do they compare? Gilead Sciences, Inc. trades at $135 (market cap $164.99B), while Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 trades at $45.01. The key difference: Gilead Sciences, Inc. pays a 2.47% dividend while Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 nearer its low. Which is the better fit depends on your goals.
| GILD | USOI | |
|---|---|---|
Market Cap | $164.99B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $155.80 | $61.17 |
52-Week Low | $110.56 | $42.27 |
Enterprise Value | $188.06B | — |
Dividend Yield | 2.47% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
USOI (Credit Suisse X-Links Crude Oil Shares Covered Call ETN) trades at $45.05, up 0.2% with a bearish technical signal from moving averages. The ETN provides exposure to oil-linked covered call strategies, generating high yields but with complex risk exposure. Recent coverage highlights its unique structure and high yield potential amid shifting market dynamics.
The outlook remains cautious given the bearish technical setup and complex ETN structure. While the high yield strategy offers income potential, investors face significant commodity price volatility and counterparty risk. The lack of traditional equity fundamentals requires careful risk assessment of the underlying oil exposure and issuer creditworthiness.
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →USOI is an Exchange-Traded Note (ETN) issued by UBS that provides exposure to a covered call strategy on the United States Oil Fund (USO). It aims to generate high monthly income by capturing option premiums from the hypothetical sale of out-of-the-money call options on oil shares, offering a way to profit from crude oil's volatility even in a flat or range-bound market.
Read more on USOI →